AMPEL BioSolutions Seeks $12.5M to Market its Personalized Blood Test for Lupus

AMPEL BioSolutions is seeking $12.5 million in funding to market LuGene, a personalized blood test that uses genetic information from a patient to predict treatment response and lupus flares. The company has initiated a Series A round of financing, which refers to the first significant step of...